ENZASTAURIN AND FRAGILE HISTIDINE TRIAD (FHIT)-INCREASING AGENTS FOR THE TREATMENT OF PULMONARY HYPERTENSION

• 收藏
• 分享

专利权人:

The Board of Trustees of the Leland Stanford Junior University

发明人:

Edda SPIEKERKOETTER,Svenja DANNEWITZ PROSSEDA,Xuefei TIAN,Purvesh KHATRI

申请号：

US16614778

公开号：

US20200206214A1

申请日:

2018.05.18

申请国别(地区):

US

年份:

2020

代理人:

摘要：

The present invention provides methods for treatment or prevention of pulmonary hypertension and emphysema using agents that increase activity of FHIT, such as Enzastaurin. Included are methods for using levels of FHIT and/or BMPR2, and checking for mutations in FHIT and/or BMPR2, to select patients for treatment or to monitor effectiveness of treatment. The invention is based on evidence that Enzastaurin prevents and reverses pulmonary hypertension induced in animal model systems, and that it acts by up-regulation of FHIT and/or BMPR2.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/